270 related articles for article (PubMed ID: 25395421)
1. Loss of TET2 has dual roles in murine myeloproliferative neoplasms: disease sustainer and disease accelerator.
Kameda T; Shide K; Yamaji T; Kamiunten A; Sekine M; Taniguchi Y; Hidaka T; Kubuki Y; Shimoda H; Marutsuka K; Sashida G; Aoyama K; Yoshimitsu M; Harada T; Abe H; Miike T; Iwakiri H; Tahara Y; Sueta M; Yamamoto S; Hasuike S; Nagata K; Iwama A; Kitanaka A; Shimoda K
Blood; 2015 Jan; 125(2):304-15. PubMed ID: 25395421
[TBL] [Abstract][Full Text] [Related]
2. Distinct effects of concomitant Jak2V617F expression and Tet2 loss in mice promote disease progression in myeloproliferative neoplasms.
Chen E; Schneider RK; Breyfogle LJ; Rosen EA; Poveromo L; Elf S; Ko A; Brumme K; Levine R; Ebert BL; Mullally A
Blood; 2015 Jan; 125(2):327-35. PubMed ID: 25281607
[TBL] [Abstract][Full Text] [Related]
3. TET2 loss, a rescue of JAK2V617F HSCs.
Vainchenker W; Plo I
Blood; 2015 Jan; 125(2):212-3. PubMed ID: 25573967
[TBL] [Abstract][Full Text] [Related]
4. [Genetic and epigenetic abnormalities in myeloproliferative neoplasms].
Kameda T; Shide K; Shimoda K
Rinsho Ketsueki; 2015 Jun; 56(6):614-22. PubMed ID: 26256870
[TBL] [Abstract][Full Text] [Related]
5. [Relationship between TET2 Gene SNP rs3733609 C/T and JAK2V617F Allele Burden in Patients with Myeloproliferative Neoplasms].
Xiao X; Liu XL; Shen XH; Deng MY; Liu SF; Zhang GS
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2019 Oct; 27(5):1574-1579. PubMed ID: 31607314
[TBL] [Abstract][Full Text] [Related]
6. Gene expression profiling of loss of TET2 and/or JAK2V617F mutant hematopoietic stem cells from mouse models of myeloproliferative neoplasms.
Kameda T; Shide K; Yamaji T; Kamiunten A; Sekine M; Hidaka T; Kubuki Y; Sashida G; Aoyama K; Yoshimitsu M; Abe H; Miike T; Iwakiri H; Tahara Y; Yamamoto S; Hasuike S; Nagata K; Iwama A; Kitanaka A; Shimoda K
Genom Data; 2015 Jun; 4():102-8. PubMed ID: 26484191
[TBL] [Abstract][Full Text] [Related]
7. Mutation in TET2 in myeloid cancers.
Delhommeau F; Dupont S; Della Valle V; James C; Trannoy S; Massé A; Kosmider O; Le Couedic JP; Robert F; Alberdi A; Lécluse Y; Plo I; Dreyfus FJ; Marzac C; Casadevall N; Lacombe C; Romana SP; Dessen P; Soulier J; Viguié F; Fontenay M; Vainchenker W; Bernard OA
N Engl J Med; 2009 May; 360(22):2289-301. PubMed ID: 19474426
[TBL] [Abstract][Full Text] [Related]
8. The role of the JAK2 GGCC haplotype and the TET2 gene in familial myeloproliferative neoplasms.
Olcaydu D; Rumi E; Harutyunyan A; Passamonti F; Pietra D; Pascutto C; Berg T; Jäger R; Hammond E; Cazzola M; Kralovics R
Haematologica; 2011 Mar; 96(3):367-74. PubMed ID: 21173100
[TBL] [Abstract][Full Text] [Related]
9. Overview of Transgenic Mouse Models of Myeloproliferative Neoplasms (MPNs).
Dunbar A; Nazir A; Levine R
Curr Protoc Pharmacol; 2017 Jun; 77():14.40.1-14.40.19. PubMed ID: 28640953
[TBL] [Abstract][Full Text] [Related]
10. Genetic analysis of transforming events that convert chronic myeloproliferative neoplasms to leukemias.
Abdel-Wahab O; Manshouri T; Patel J; Harris K; Yao J; Hedvat C; Heguy A; Bueso-Ramos C; Kantarjian H; Levine RL; Verstovsek S
Cancer Res; 2010 Jan; 70(2):447-52. PubMed ID: 20068184
[TBL] [Abstract][Full Text] [Related]
11. The thrombopoietin receptor, MPL, is critical for development of a JAK2V617F-induced myeloproliferative neoplasm.
Sangkhae V; Etheridge SL; Kaushansky K; Hitchcock IS
Blood; 2014 Dec; 124(26):3956-63. PubMed ID: 25339357
[TBL] [Abstract][Full Text] [Related]
12. LNK mutation studies in blast-phase myeloproliferative neoplasms, and in chronic-phase disease with TET2, IDH, JAK2 or MPL mutations.
Pardanani A; Lasho T; Finke C; Oh ST; Gotlib J; Tefferi A
Leukemia; 2010 Oct; 24(10):1713-8. PubMed ID: 20724988
[TBL] [Abstract][Full Text] [Related]
13. Single-cell approaches identify the molecular network driving malignant hematopoietic stem cell self-renewal.
Shepherd MS; Li J; Wilson NK; Oedekoven CA; Li J; Belmonte M; Fink J; Prick JCM; Pask DC; Hamilton TL; Loeffler D; Rao A; Schröder T; Göttgens B; Green AR; Kent DG
Blood; 2018 Aug; 132(8):791-803. PubMed ID: 29991556
[TBL] [Abstract][Full Text] [Related]
14. Mechanisms of mutations in myeloproliferative neoplasms.
Levine RL
Best Pract Res Clin Haematol; 2009 Dec; 22(4):489-94. PubMed ID: 19959098
[TBL] [Abstract][Full Text] [Related]
15. New mutations and pathogenesis of myeloproliferative neoplasms.
Vainchenker W; Delhommeau F; Constantinescu SN; Bernard OA
Blood; 2011 Aug; 118(7):1723-35. PubMed ID: 21653328
[TBL] [Abstract][Full Text] [Related]
16. JAK2V617F Mutant Megakaryocytes Contribute to Hematopoietic Aging in a Murine Model of Myeloproliferative Neoplasm.
Lee S; Wong H; Castiglione M; Murphy M; Kaushansky K; Zhan H
Stem Cells; 2022 Apr; 40(4):359-370. PubMed ID: 35260895
[TBL] [Abstract][Full Text] [Related]
17. Genetics of the myeloproliferative neoplasms.
Abdel-Wahab O
Curr Opin Hematol; 2011 Mar; 18(2):117-23. PubMed ID: 21307773
[TBL] [Abstract][Full Text] [Related]
18. Clonal analysis of TET2 and JAK2 mutations suggests that TET2 can be a late event in the progression of myeloproliferative neoplasms.
Schaub FX; Looser R; Li S; Hao-Shen H; Lehmann T; Tichelli A; Skoda RC
Blood; 2010 Mar; 115(10):2003-7. PubMed ID: 20061559
[TBL] [Abstract][Full Text] [Related]
19. Description of a knock-in mouse model of JAK2V617F MPN emerging from a minority of mutated hematopoietic stem cells.
Mansier O; Kilani B; Guitart AV; Guy A; Gourdou-Latyszenok V; Marty C; Parrens M; Plo I; Vainchenker W; James C
Blood; 2019 Dec; 134(26):2383-2387. PubMed ID: 31697834
[TBL] [Abstract][Full Text] [Related]
20. R723, a selective JAK2 inhibitor, effectively treats JAK2V617F-induced murine myeloproliferative neoplasm.
Shide K; Kameda T; Markovtsov V; Shimoda HK; Tonkin E; Fang S; Liu C; Gelman M; Lang W; Romero J; McLaughlin J; Bhamidipati S; Clough J; Low C; Reitsma A; Siu S; Pine P; Park G; Torneros A; Duan M; Singh R; Payan DG; Matsunaga T; Hitoshi Y; Shimoda K
Blood; 2011 Jun; 117(25):6866-75. PubMed ID: 21531978
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
